174 related articles for article (PubMed ID: 11051391)
1. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.
Kurihara T; Niimi A; Maeda A; Shigemoto M; Yamashita K
Am J Gastroenterol; 2000 Oct; 95(10):2990-2. PubMed ID: 11051391
[No Abstract] [Full Text] [Related]
2. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.
Nakai S; Masaki T; Kurokohchi K; Deguchi A; Nishioka M
Am J Gastroenterol; 2000 Jan; 95(1):326-7. PubMed ID: 10638623
[No Abstract] [Full Text] [Related]
3. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy.
Kurihara T; Maeda A; Shigemoto M; Yamashita K; Hashimoto E
Am J Gastroenterol; 2002 Jan; 97(1):212-4. PubMed ID: 11808959
[No Abstract] [Full Text] [Related]
4. [Cholestatic liver diseases--diagnosis and therapy. 3: Therapy of primary biliary cirrhosis].
Leuschner U
Fortschr Med; 1998 Jan; 116(1-2):37-9. PubMed ID: 9522537
[No Abstract] [Full Text] [Related]
5. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid.
Abbas G; Lindor KD
Expert Opin Pharmacother; 2010 Feb; 11(3):387-92. PubMed ID: 20102304
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
9. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
11. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
[TBL] [Abstract][Full Text] [Related]
12. A novel treatment for refractory primary biliary cirrhosis?
Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
[TBL] [Abstract][Full Text] [Related]
13. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Walker LJ; Newton J; Jones DE; Bassendine MF
Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
[No Abstract] [Full Text] [Related]
14. [Ursodeoxycholic acid in primary biliary cirrhosis. 2: Prospective long-term study of 21 patients].
Eisenburg J; Eder M; Spengler U; Berg PA; Caselmann W; Mannes AG; Muntau A
Fortschr Med; 1988 Nov; 106(34):695-8. PubMed ID: 3145247
[No Abstract] [Full Text] [Related]
15. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia.
Willot S; Uhlen S; Michaud L; Briand G; Bonnevalle M; Sfeir R; Gottrand F
Pediatrics; 2008 Dec; 122(6):e1236-41. PubMed ID: 19029197
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of primary biliary cirrhosis. The effect of ursodeoxycholic acid is questioned now].
Broomé U
Lakartidningen; 2000 May; 97(21):2585-7. PubMed ID: 10881517
[No Abstract] [Full Text] [Related]
17. [Treatment of autoimmune hepatic diseases].
Bueverov AO
Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604
[TBL] [Abstract][Full Text] [Related]
18. New weapon for primary biliary cirrhosis from Japan.
Zeniya M
J Gastroenterol; 2003; 38(6):619-20. PubMed ID: 12858848
[No Abstract] [Full Text] [Related]
19. [Management of PBC cases failing to respond to UDCA].
Tanaka A
Nihon Shokakibyo Gakkai Zasshi; 2013 Jan; 110(1):16-21. PubMed ID: 23303227
[No Abstract] [Full Text] [Related]
20. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
Angulo P; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
